This guidance is intended for risk assessors and developers creating applications for devices handling OFFICIAL data, providing them assistance on how to properly manage and protect this information.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
